Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based study
{{output}}
Aims: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a pillar of therapy among people with both type 2 diabetes (T2D) and heart failure (HF). Despite being a population at high-risk of cardio-renal events, little is known... ...
